Equities Analysts Offer Predictions for ACXP Q1 Earnings

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Acurx Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.14) per share for the quarter, up from their prior estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.56) EPS and FY2028 earnings at ($1.57) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02.

Acurx Pharmaceuticals Price Performance

Shares of ACXP opened at $0.42 on Friday. The company has a 50-day moving average of $0.69 and a two-hundred day moving average of $1.24. Acurx Pharmaceuticals has a one year low of $0.40 and a one year high of $3.33. The stock has a market cap of $9.33 million, a price-to-earnings ratio of -0.39 and a beta of -1.71.

Insider Transactions at Acurx Pharmaceuticals

In related news, CEO David P. Luci bought 49,261 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was bought at an average price of $1.01 per share, with a total value of $49,753.61. Following the purchase, the chief executive officer now directly owns 1,097,458 shares of the company’s stock, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 29.60% of the stock is currently owned by insiders.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC increased its stake in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 11.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 329,076 shares of the company’s stock after acquiring an additional 34,001 shares during the period. Prospect Financial Services LLC owned 1.93% of Acurx Pharmaceuticals worth $268,000 as of its most recent filing with the SEC. 11.53% of the stock is owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.